Jasper Therapeutics, Inc.
NNASDAQ:JSPRCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jeet Mahal
- Full Time Employees
- 22
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 2200 Bridge Pkwy Redwood City CA United States 94065
- IPO Date
- Nov 20, 2019
- CIK
- 0001788028
- Website
- jaspertherapeutics.com
- Similar Companies
- Business
- Jasper Therapeutics, Inc. (Nasdaq: JSPR) is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cells and hematopoietic stem cells to treat chronic immunological, inflammatory, and mast cell-driven diseases. The company advances briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells; it is evaluating subcutaneous formulations of briquilimab in ongoing Phase 1b/2a trials including the BEACON study for chronic spontaneous urticaria (CSU) in patients refractory to antihistamines and omalizumab, the SPOTLIGHT study for chronic inducible urticaria (CIndU) such as cold urticaria and symptomatic dermographism, and the paused ETESIAN study for allergic asthma; prior evaluations of briquilimab also include its use as a conditioning agent in stem cell transplantation for hematologic malignancies, severe combined immunodeficiency, and sickle cell disease. Jasper Therapeutics operates in the biopharmaceutical sector, serving patients with mast cell-driven conditions like CSU, CIndU, and asthma, as well as those requiring stem cell therapies for blood disorders, with clinical trials conducted at sites in the US, EU, and Canada. Founded in 2018 and headquartered in Redwood City, California, the company maintains full worldwide rights to briquilimab across all indications and reports recent advancements such as continued patient enrollment in BEACON and SPOTLIGHT studies with additional data anticipated in early 2026 to support dose selection for a planned Phase 2b CSU trial mid-2026, a $45 million private placement in October 2024, and a $30 million public offering in October 2025.
Company News
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jasper Closes Kira Deal, Extends Cash Runway
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
Here Are Monday’s Top Wall Street Analyst Research Calls: APA Corporation, Cheniere Energy, Crown Castle, Hut 8, MongoDB, Red Rock Resorts, Super Micro Computer, Terawulf, and More
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
Jasper Therapeutics (NASDAQ:JSPR) Stock Price Down 7.3% – Time to Sell?
Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data Transcript
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation